| Test Code |
Procedure |
| 300908 |
Abnormal APTT/Prothrombin Time Reflexive Evaluation
(APTT, Prothrombin Time/INR, Thrombin Time) Note: Additional assays as necessary will be performed at an additional charge to determine the cause of the abnormality. |
| 300716 |
Activated Protein C Resistance (APCR) with Factor V Deficient Plasma |
| 300737 |
Activated Protein C Resistance (APCR) without Factor V Deficient Plasma |
| |
ADAMTS-13 - see 300326- von Willebrand Protease Activity and Protease Inhibitor |
| 300039 |
Alpha-2-Antiplasmin Assay |
| 300233 |
Anti-Annexin V IgG, IgM *RUO* |
| 300034 |
Anticardiolipin Antibodies, IgA, IgG, IgM |
| 300165 |
Anticardiolipin Antibodies, IgG, IgM |
| 300164 |
Anticardiolipin Antibody, IgA |
| 300161 |
Anticardiolipin Antibody, IgG |
| 300162 |
Anticardiolipin Antibody, IgM |
| 300153 |
Antiphosphatidylserine (APTS) IgG, IgM |
| 300918 |
Antiphospholipid Syndrome Comprehensive Evaluation
(APTT, Immediate Mixing Studies, Anticardiolipin Antibodies (IgG, IgM, IgA), Antiphosphatidylserine Antibodies (IgG, IgM), Beta-2-Glycoprotein I Antibodies (IgG, IgM, IgA), Antiprothrombin Antibodies (IgG, IgM), DRVVT, Hexagonal Phospholipid Neutralization, Platelet Neutralization Procedure) |
| 300230 |
Antiprothrombin Antibodies IgG, IgM |
| 300030 |
Antithrombin Activity |
| 300033 |
Antithrombin Antigen |
| |
APCR - see 300716 - Activated Protein C Resistance |
| 300040 |
APTT |
| 300806 |
APTT Mixing Studies
(APTT, APTT 1:1 NP Mix, APTT 1:1 NP Control Mix, APTT 1:1 Saline Mix, APTT 1:1 NP 60 min. Incubation, APTT 1:1 NP Control 60 min. Incubation) |
| |
ArixtraŽ - see 300864- Heparin Anti-Xa Fondaparinux |
| 300353 |
AspirinWorks |
| 300166 |
Beta-2 Glycoprotein I, IgA, IgG, IgM |
| 300909 |
Bleeding Diathesis with a Normal APTT/PT Evaluation
(Factor VIII Activity, von Willebrand Factor Activity, von Willebrand Factor Antigen, Factor IX Activity, Factor XI Activity, Plasminogen Activator Inhibitor - 1 Activity, Alpha 2 Antiplasmin Activity, Factor XIII Activity *RUO*, Euglobulin Lysis Time) |
| 300160 |
C4b Binding Protein *RUO* |
| |
CBA - see 300314 - Collagen Binding Assay |
| 300314 |
Collagen Binding Assay
(VWF collagen binding activity *RUO*, VWF antigen, Collagen binding ratio) |
| 300924 |
Contact Factor Evaluation
(Factor XI Activity, Factor XII Activity, High Molecular Weight Kininogen
(Fitzgerald Factor) Assay, Prekallikrein (Fletcher Factor ) Assay) |
| 300312 |
C-Reactive Protein, High Sensitivity
(hs CRP) |
| 300203 |
Cryofibrinogen |
| 300749 |
CYP2C9 Polymorphism
Warfarin hypersensitivity Genotyping |
| 300415 |
D-Dimer Quantitative (Automated) |
| 300057 |
Dilute Russell's Viper Venom Test
(DRVVT) |
| |
Drug Induced Platelet Antibody - see 300521 - Platelet Antibody, Drug Induced |
| 300814 |
Ecarin Clotting Time *RUO* |
| 300403 |
Euglobulin Lysis Time |
| 300920 |
Extrinsic Pathway Evaluation Profile
(Factor II Activity, Factor V Activity,
Factor VII Activity, Factor X Activity) |
| 300700 |
Factor Inhibitor Screen (APTT, PT, Thrombin Time, APTT 1:1 NP, APTT 1:1 Saline, APTT 1:1 NP 60 min. incubation, APTT 1:1 NP Control 60 min. incubation, Inhibitor Screen interpretation) |
| 300100 |
Factor II Activity (Prothrombin Activity) |
| 120736 |
Factor II Gene Mutation (Prothrombin G20210A) |
| 300724 |
Factor II Inhibitor (Bethesda)
(APTT, PT, PT 1:1 NP, PT 1:1 NP 60 min. incubation, PT 1:1 NP control 60 min. incubation, Factor II Activity, Factor II Bethesda Titer) |
| 300101 |
Factor V Activity |
| 300706 |
Factor V Inhibitor (Bethesda)
(APTT, PT, PT 1:1 NP, Factor V Activity, Factor V Bethesda Titer) |
| 120719 |
Factor V Leiden Mutation |
| 300102 |
Factor VII Activity |
| 300112 |
Factor VII Antigen *RUO* |
| 300721 |
Factor VII Inhibitor (Bethesda) (APTT, PT, PT 1:1 NP, Factor VII Activity, Factor VII Bethesda Titer) |
| 300103 |
Factor VIII Activity |
| 300690 |
Factor VIII Antibody, Immunologic |
| 300208 |
Factor VIII Antigen |
| 300188 |
Factor VIII Bethesda Titer
(Factor VIII Activity and Factor VIII Bethesda titer only) |
| 300214 |
Factor VIII Chromogenic Activity |
| 300213 |
Factor VIII Chromogenic Activity - RefactoTM |
| 300701 |
Factor VIII Inhibitor Human (Bethesda)
(APTT, APTT 1:1 NP, APTT 1:1 saline, APTT 1:1 NP 60 min. incubation, APTT 1:1 NP control 60 min. incubation, Factor VIII Activity, Factor VIII Bethesda Titer) |
| |
Factor VIII Related Antigen - see 300113 - von Willebrand Factor Antigen |
| 300104 |
Factor IX Activity |
| 300205 |
Factor IX Antigen |
| 300189 |
Factor IX Bethesda Titer
(Factor IX Activity and Factor IX Bethesda titer only) |
| 300704 |
Factor IX Inhibitor (Bethesda) (APTT, APTT 1:1 NP, APTT 1:1 saline, APTT 1:1 NP 60 min. incubation, APTT 1:1 NP control 60 min. incubation, Factor IX Activity, Factor IX Bethesda Titer) |
| 300105 |
Factor X Activity |
| 300206 |
Factor X Antigen *RUO* |
| 300211 |
Factor X Chromogenic
(for Oral Anticoagulant Therapy) |
| 300215 |
Factor X Chromogenic
(not on Oral Anticoagulant) |
| 300725 |
Factor X Inhibitor (Bethesda)
(APTT, PT, PT 1:1 NP, PT 1:1 NP 60 minute incubation, PT 1:1 NP control 60 minute incubation, Factor X Activity, Factor X Bethesda Titer) |
| 300106 |
Factor XI Activity |
| 300707 |
Factor XI Inhibitor (Bethesda)
(APTT, APTT 1:1 NP, APTT 1:1 saline, APTT 1:1 NP 60 min. incubation, APTT 1:1 NP control 60 min. incubation, Factor XI Activity, Factor XI Bethesda Titer) |
| 300107 |
Factor XII Activity |
| 300708 |
Factor XII Inhibitor (Bethesda)
(APTT, APTT 1:1 NP, APTT 1:1 saline, APTT 1:1 NP 60 min. incubation, APTT 1:1 NP control 60 min. incubation, Factor XII Activity, Factor XII Bethesda Titer) |
| 300108 |
Factor XIII Activity *RUO* |
| 300309 |
Factor XIII Inhibitor Profile *RUO* (Factor XIII Activity, Factor XIII Inhibitor Screen, Factor XIII Titer) |
| 300308 |
Factor XIII Inhibitor Screen *RUO* |
| |
FDP - see 300201 - Fibrin Degradation Products (FDP) |
| 300201 |
Fibrin Degradation Products (FDP) |
| 300202 |
Fibrin Monomer |
| 300200 |
Fibrinogen Activity |
| 300199 |
Fibrinogen Antigen |
| 300925 |
Fibrinogen Evaluation
(Fibrinogen Activity, Fibrinogen Antigen, Reptilase Time, Thrombin Time, Thrombin Time Mixing Studies) |
| 300913 |
Fibrinolysis Evaluation
(Alpha-2-Antiplasmin, D-Dimer Quantitative, Euglobulin Lysis Time, Fibrin Degradation Products, Plasminogen Activator Inhibitor-1 Activity, Plasminogen Activity, Tissue
Plasminogen Activator Antigen) |
| |
Fitzgerald Factor (HMW Kininogen) - see - 300123 - High Molecular Weight Kininogen |
| |
Fletcher Factor (Prekallikrein) Assay - see - 300121 Preallikrein Assay |
| |
FSP (Fibrin Split Products) - see 300201 - Fibrin Degradation Products (FDP) |
| 300917 |
Heart Disease and Stroke Risk Profile
(Fibrinogen Activity, High Sensitivity
CRP, Homocysteine, Lipoprotein (a),
von Willebrand Factor Antigen) |
| 300927 |
Heart Disease and Stroke Risk Profile-
Follow-up
(APTT, 11-Dehydro Thromboxane B2/Creatinine Ratio *RUO*, Factor VII Activity, Plasminogen Activator Inhibitor-1 Activity) |
| 300600 |
Heparin Anti-Xa (Unfractionated) |
| 300864 |
Heparin Anti-Xa Fondaparinux (ArixtraŽ) |
| 300602 |
Heparin Anti-Xa LMWH
(Dalteparin, Enoxaparin) |
| 300133 |
Heparin Cofactor II *RUO* |
| |
Heparin Induced Antibody Assay, Functional see 300082 - Serotonin Release Assasy (C4) |
| 300935 |
Heparin Induced Antibody Evaluation
(Heparin Induced Platelet Antibody, HITA normalized OD ratio, Serotonin Release Assay (specify heparin type)) |
| 300522 |
Heparin-Induced Platelet Antibody, Immunologic
(Heparin Induced Antibody, HITA normalized OD ratio) |
| 300528 |
Heparin-Induced Antibody Titer |
| 300937 |
Heparin Induced Antibody Reflexive Evaluation
(Heparin Induced Platelet Antibody, HITA normalized OD ratio, Reflex to Serotonin Release Assay if antibody by ELISA is positive or borderline) |
| 300139 |
Heparin Solution Quantitative Assay |
| 300144 |
Hexagonal Phospholipid Neutralization |
| 300123 |
High Molecular Weight Kininogen (Fitzgerald Factor Assay) |
| |
See 300312 - C-Reactive Protein, High Sensitivity |
| 300727 |
Homocysteine |
| 300531 |
HPA-1a (PLA-1Platelet Antigen) Genotyping (PLA2 Polymorphism Detection) |
| 300734 |
HR2 Haplotype (Factor V HR2), A4070G Polymorphism |
| 300229 |
Immunoglobulin IgA, Quantitative |
| 300227 |
Immunoglobulin IgG, Quantitative |
| 300228 |
Immunoglobulin IgM, Quantitative |
| 603005 |
Immunoglobulin Profile (IgA, IgG, & IgM) |
| 300921 |
Intrinsic Pathway Evaluation Profile
(Factor VIII Activity, Factor IX Activity, Factor XI Activity, Factor XII Activity) |
| 300056 |
Kaolin Clotting Time (KCT) |
| 300715 |
Lipoprotein (a) |
| 300916 |
Lupus Anticoagulant and Anticardiolipin Antibody Confirmatory Profile
(APTT, APTT Immediate Mixing Studies, Prothrombin Time/INR, Anticardiolipin Antibody (IgG, IgM), Dilute Russell's Viper Venom Test, Thrombin Time, Hexagonal Phospholipid Neutralization, Platelet Neutralization Procedure) |
| 300906 |
Lupus Anticoagulant and
Anticardiolipin Antibody Evaluation
(APTT, APTT Immediate Mixing Studies, Prothrombin Time/INR, Anticardiolipin Antibody (IgG, IgM), Dilute Russell's Viper Venom Test, Thrombin Time, hexagonal phospholipid neutralization) |
| 300939 |
Markers of Coagulation Activation
(Thrombin-Antithrombin Complex (TAT), Prothrombin Fragment 1.2, D-Dimer quant) |
| 300934 |
Menorrhagia Evaluation
(APTT, Prothrombin Time/INR, Factor VIII Activity, von Willebrand Factor Activity, von Willebrand Factor Antigen, Factor XI Activity) |
| 300744 |
Methylmalonic Acid, Serum*** |
| 300711 |
MMP-9 *RUO*
(Matrix Metalloproteinase-9)
|
| 120740 |
MTHFR A1298C Mutation
(Methylene Tetrahydrofolate Reductase) |
| 120733 |
MTHFR C677T Mutation
(Methylene Tetrahydrofolate Reductase) |
| 129300 |
MTHFR Reflex
(Heterozygous reflexes to MTHFR A1298C) |
| 300933 |
Oral Contraceptive/Hormone Replacement Therapy Thrombotic Risk Evaluation
(Antithrombin Activity, Factor II Gene Mutation (Prothrombin G20210A), Factor V Leiden, Protein C Activity, Protein S Antigen Free) |
| 300995 |
Pathology Consultation (Coagulation) - Limited |
| |
PF4 Antibody - see 300522 - Heparin Induced Platelet Antibody, Immunologic |
| 300726 |
PIVKA-II *RUO* |
| 300126 |
Plasminogen Activator Inhibitor-1
(PAI-1) Activity |
| 300128 |
Plasminogen Activator Inhibitor-1
(PAI-1) Antigen |
| 129100 |
Plasminogen Activator Inhibitor-1, 4G/5G Genotyping *RUO* (PAI-1 polymorphism) |
| 300400 |
Plasminogen Activity |
| 300408 |
Plasminogen Antigen |
| 300523 |
Platelet Antibody, Direct |
| 300521 |
Platelet Antibody Drug-Induced*** |
| 300520 |
Platelet Antibody Screen, Indirect
(HLA, Platelet Glycoprotein) |
| 300936 |
Platelet Antibody Profile (Platelet antibody screen, platelet antibody direct) |
| 300504 |
Platelet Factor 4 |
| 300805 |
Platelet Neutralization Procedure |
| 300524 |
Platelet Specific Antibody (GP IIb/IIIa) |
| |
Platelet Specific Antigen PLA1 (HPA-1a) - see 300531 - HPA-1a (PLA 1 Platelet Antigen Genotyping PLA 2 Polymorphism Detection) |
| |
Platelet Specific Antigen-2 (PLA2)
Polymorphism (HPA-1b) - see 300531- HPA-1a (PLA 1 Platelet Antigen Genotyping PLA 2 Polymorphism Detection)
|
| 300121 |
Prekallikrein (Fletcher Factor) Assay |
| |
Prolonged Prothrombin Time or APTT - see 300908 - Abnormal APTT/Prothrombin Time Evaluation |
| 300204 |
Protein C Activity and Protein S Activity, Protein C Antigen and Protein S Antigen, Total |
| 300149 |
Protein C Activity and Protein S Activity |
| 300177 |
Protein C Activity and Protein S Antigen, Free |
| 300142 |
Protein C Antigen and Protein S Antigen, Total |
| 300035 |
Protein C Activity (Chromogenic) |
| 300036 |
Protein C Antigen |
| 300067 |
Protein C Antigen/Factor VII Antigen Ratio *RUO*
|
| 300032 |
Protein C Antigen, Protein S Antigen/ Factor VII Antigen Ratios *RUO* |
| 300088 |
Protein S Activity |
| 300087 |
Protein S Antigen, Free |
| 300038 |
Protein S Antigen, Total |
| 300929 |
Protein S Antigen, Total and Free |
| 300059 |
Protein S Antigen/Factor VII Antigen Ratio *RUO* |
| 300928 |
Protein S Evaluation (C4b Binding Protein *RUO*, Protein S Activity, Protein S Antigen Free, Protein S Antigen Total) |
| 300340 |
Protein Z Antigen *RUO* |
| 300718 |
Prothrombin Fragment 1+ 2, monoclonal |
| |
Prothrombin Gene 20210A Mutation
(Factor II Mutation) - see 120736 - Factor II Gene Mutation (Prothrombin G20210A) |
| |
Prothrombin Time Abnormal Evaluation- see 300908 - Abnormal APTT/Prothrombin Time Evaluation |
| 300080 |
Prothrombin Time/INR |
| 300116 |
Prothrombin Time Mixing Studies:
PT, PT 1:1 NP, PT 1:1 NP 60 min. incubation, PT 1:1 NP 60 min. incubation control |
| 300620 |
Prothrombinase Induced Clotting Time (Refludan) |
| 300915 |
Recurrent Miscarriage/Fetal Demise /Obstetric Complications Evaluation
(APTT, Anticardiolipin Antibody (IgG, IgM, IgA), Antiphosphatidylserine (IgG, IgM), Antithrombin Activity, Beta-2 Glycoprotein I Antibody (IgG, IgM, IgA), DRVVT, Factor II Gene Mutation (Prothrombin G20210A), Factor V Mutation (Leiden), Hexagonal Phospholipid Neutralization, Homocysteine, Protein C Activity, Protein S Antigen Free.)
|
| 300940 |
Reproductive Health Thrombophilia Profile, Screening APTT, Factor XIII *RUO*, Factor II Gene Mutation (Proghrombin G20210A), Factor V Leiden Mutation, Hexagonal Phospholipid Neutralization, Antithrombin Activity, Protein C Activity (Chromagenic), Protein S Antigen, Free, Anticardiolipin IgG, IgM, IgA, Homocysteine Note: Reflex to immediate APTT mixing studies if APTT is abnormal. |
| 300941 |
Reproductive Health Thrombophilia Profile, Comprehensive
(Activated Partial Thromboplastin Time, Beta-2 GPI, IgG, IgM, IgA, Antiphosphatidylserine, IgG and IgM, Anti-Annexin V, IgG and IgM *RUO*, Anticardiolipin IgG, IgM and IgA, Anti-Prothrombin IgG and IgM, Dilute Russell's Viper Venom Time, Hexagonal Phospholipid Neutralization, Antithrombin Activity- Plasma, Protein C Activity (chromogenic), Protein S Antigen, Free, Factor XIII Activity *RUO*, PAI-1 Activity, Homocysteine, Factor II Gene Mutation (Prothrombin G20210A), Factor V Leiden, MTHFR C677T, Reflex to Immediate APTT mixing studies if APTT is abnormal) |
| 300610 |
Reptilase Time |
| |
Ristocetin Cofactor - See 300114 -
von Willebrand Factor Activity |
| 300082 |
Serotonin Release Assay (C-14) , Functional Heparin Induced Antibody Assay *** |
| 300611 |
Stypven Time (RVV) *RUO* |
| 129260 |
ThrombAssureTM (Factor II Gene Mutation (Prothrombin G20210A) , Factor V Leiden Mutation) |
| 129250 |
ThrombAssure PlusTM (Factor II Gene Mutation (Prothrombin G20210A), Factor V Leiden Mutation, HR2 Haplotype (A4070G), MTHFR C677T) |
| 300931 |
ThrombAssure EnhancedTM
(Factor II Gene Mutation (Prothrombin G20210A), Factor V Leiden Mutation, Anticardiolipin Antibody (IgG, IgM, IgA), Antithrombin Activity, DRVVT, Hexagonal Phospholipid Neutralization, Homocysteine, Protein C Activity, Protein S Antigen Free) |
| 300932 |
ThrombAssure InheritedTM
(Factor II Gene Mutation (Prothrombin G20210A), Factor V Leiden Mutation, Antithrombin Activity Plasma, Protein C Activity, Protein S Antigen Free) |
| 300714 |
Thrombin-Antithrombin Complex |
| 300807 |
Thrombin Time |
| 300813 |
Thrombin Time Mixing Studies
(Thrombin Time, Thrombin Time 1:1 NP Mix, Thrombin Time Heparin Neutralization) |
| 300907 |
Thrombotic Marker Evaluation
(D-Dimer Quantitative, Fibrin Monomer, Prothrombin Fragment 1+2, Thrombin-Antithrombin Complex) |
| 300134 |
Tissue Plasminogen Activator (TPA)
Activity |
| 300125 |
Tissue Plasminogen Activator (TPA)
Antigen |
| 300804 |
Tissue Thromboplastin Inhibition Test
(TTIT) |
| 300914 |
Venous Occlusion Evaluation
(Plasminogen Activator Inhibitor - 1 Activity - Pre-occlusion, Tissue Plasminogen Activator Antigen - Pre-occlusion, Tissue Plasminogen Activator Antigen - Post-occlusion) |
| 300901 |
Venous Thrombosis (Hypercoagulability) Evaluation
(Activated Protein C Resistance, Anticardiolipin Antibody (IgG, IgM), Antithrombin Activity, Factor II Gene Mutation (Prothrombin G20210A), DRVVT, Hexagonal Phospholipid Neutralization, Homocysteine, Protein C Activity (chromogenic), Protein S Antigen Free, Factor VIII Activity)
Note: Reflex to Factor V Leiden if APCR is abnormal |
| 300905 |
Venous Thrombosis Evaluation Appended (Factor IX Activity, Factor XI Activity, Fibrinogen Activity, Fibrinogen Antigen, HR2 Haplotype (A4070G), Lipoprotein (a), Plasminogen Activity) |
| 300903 |
Venous Thrombosis (Hypercoagulability) Evaluation for Patients on Oral Anticoagulant Therapy
(Activated Protein C Resistance, Anticardiolipin Antibody (IgG, IgM), Antithrombin Activity, Factor II Gene Mutation (Prothrombin G20210A), DRVVT, Hexagonal Phospholipid Neutralization, Homocysteine, Protein C Antigen, Protein S Antigen Total, Factor VII Antigen *RUO*, Factor VIII Activity, Protein C Antigen/Factor VII Antigen Ratio *RUO*, Protein S Antigen/Factor VII Antigen Ratio *RUO*
Note: Reflex to Factor V Leiden if APCR is abnormal. |
| 300326 |
von Willebrand Cleaving Protease Profile (ADAMTS13)
(von Willebrand Protease Activity and von Willebrand Protease Inhibitor)*** |
| 300910 |
von Willebrand Disease Evaluation
(APTT, Collagen Binding Ratio, von Willebrand Factor Collagen Binding Activity, Factor VIII Activity, von Willebrand Factor Activity, von Willebrand Factor Antigen) |
| 300114 |
von Willebrand Factor Activity
(Ristocetin Cofactor) |
| 300113 |
von Willebrand Factor Antigen
(Factor VIII Related Antigen) |
| 300117 |
von Willebrand Factor Multimers |
| 300318 |
von Willebrand Factor Protease Inhibitor*** |
| 300115 |
von Willebrand Factor Type 2 N Binding*** |
| 300919 |
von Willebrand Inhibitor Profile
(Factor VIII Activity, von Willebrand Factor Antigen, von Willebrand Factor Activity, von Willebrand Activity NP Control, von Willebrand Activity 1:1 NP Mixing Study, von Willebrand Collagen Binding Activity, Collagen Binding ratio, Pathologist interpretation) |
| |
Warfarin Hyper - responsiveness Genotyping - see 300749- CYP2C9 Polymorphism |
